كتاب
ADVANCED/METASTATIC BREAST CANCER
- References
1. Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475-1495
2. Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649.
3. Lee CI, Gold LS, Nelson HD, et al. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2015;24(1):3-11.
4. Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol. 2011;29(22):3072-3077.
5. Komorowski AS, Warner E, MacKay HJ, et al. Incidence of brain me- tastases in nonmetastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54-e64.
6. Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck
N, Bondarenko I, Masuda N et al.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC:
Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III
Randomized Study.Clin Cancer Res. 2022 Aug
15;28(16):3433-3442. doi: 10.1158/1078-0432.CCR-22-0305.
7. Goetz MP, Toi M, Huober J, Sohn J, Trédan O, Park IH et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3., Ann Oncol. 2024 Aug;35(8):718-727.
8. Ribociclib plus Endocrine Therapy in Early Breast Cancer.Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy et al. N Engl J Med. 2024 Mar 21;390(12):1080-1091.
9. Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a ran- domized study. J Natl Cancer Inst. 2000;92(11):903-911.
10. Baselga J, Campone M, Piccart M, et al. Everolimus in post- menopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
11. Cook MM, Al Rabadi L, Kaempf AJ, et al. Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4/6 inhibitor therapy. Oncologist. 2021;26(2):101-106.
12. Jerusalem G, de Boer RH, Hurvitz S, et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor- positive, HER2-negative advanced breast cancer: the BOLERO-6 ran- domized clinical trial. JAMA Oncol. 2018;4(10):1367-1374.
13. Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014;25(12):2357-2362.
14. Im SA, Gennari A ,Park YH, Kim JH et al., Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer, Ann. Oncol, 8,(3): 1-24, 2023
15. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anas- trozole versus anastrozole alone for the treatment of post- menopausal women with human epidermal growth factor receptor 2- positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009;27(33):5529-5537.
16. Yuan Z, Huang J-J, Hua X, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: the SYSUCC-002 randomized clinical trial. J Clin Oncol. 2021;39(suppl 15):1003.
17. Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line tras- tuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36(28):2826-2835.
18. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced hu- man epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(14):1594-1600
19. Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhib- itor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. J Clin Oncol. 2018;36(8):741-748.
20. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for post- menopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538-5546.
22. Bartsch R, Cameron D, Ciruelos E, Criscitiello C, Curigliano G, Duhoux FP, Foukakis T, Gligorov J, Harbeck N, LeVasseur N, Okines A, Penault-Llorca F, Müller V.Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer.Cancer Treat Rev. 2025 Jan;132:102853.
23. ASCO Educational Book: 2022,https://ascopubs.org/doi/pdf/10.1200/EDBK_351222#:~:text=In%20later%20lines%20of%20therapy,in%20the%20late%2Dline%20scenario.
24. Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG., Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis.
Int J Radiat Oncol Biol Phys. 2022 Dec 1;114(5):919-935.
25. Demirors B, Goktepe B, Medeck H, Ozbas S, Soran A, et al., The Role of Primary Surgery in De Novo Metastatic Breast Carcinoma.Eur J Breast Health. 2023 Apr 1;19(2):110-114.
26. Gennari A, André F, Barrios C H et al., ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 32,12:1475-1495.
27. Le Rhun E, Guckenberger M, Smits M, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32(11): 1332-1347.
28. John Sieh Dumbuya,Bashir Ahmad, Cizheng Zeng, Xiuling Chen & Jun Lu, Assessing the effectiveness of measurement scales in evaluating the health-related quality of life in rare disease patients after treatment: a systematic review Health and Quality of Life Outcomes, 22,108 (2024).
